Mark E. Dmytruk - Apr 6, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Apr 6, 2023
Transactions value $
-$986
Form type
4
Date filed
4/11/2023, 05:03 PM
Previous filing
Apr 5, 2023
Next filing
May 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +1.64K +0.28% 577K Apr 6, 2023 Direct F1, F2
transaction DNA Class A Common Stock Sale -$986 -740 -0.13% $1.33 576K Apr 10, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Class B Common Stock Options Exercise -1.64K -0.25% 648K Apr 6, 2023 Class A Common Stock 1.64K Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F2 Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F3 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F4 Includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Financial Officer